Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today ...
NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.
Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright ...
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasionâ„¢ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 ...
An iPSC manufacturing strategy for cell therapies drops the cost of goods sold to about $5,000 per dose, down from $115,000 per dose for autologous therapeutics and $40,000 per dose for allogeneic ...
Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
Morning Overview on MSN
New bioreactor makes 40M human macrophages a week from stem cells
A benchtop bioreactor system developed at Hannover Medical School can produce up to 40 million human immune cells per week ...
Since their discovery in 2006 by Takahashi and Yamanaka, induced pluripotent stem cells (iPSCs) have seen a remarkable surge in their application within academic and industrial research. Generated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results